Skip to main content
PLX logo

PLX

Protalix Biotherapeutics, Inc.

$2.33

1.48%

Trade Ideas Performance

Latest Closed Trade Idea

$2.33

1.48%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

2

Social

8

About

Events of Protalix Biotherapeutics, Inc. (PLX)

Protalix BioTherapeutics reported its fiscal year 2025 financial and business results, leading to a share decline of 20.8%. Protalix issued a letter to stockholders, providing an update on its focus for 2026, including the advancement of PRX-115 and its strategic focus on rare kidney diseases. The company announced a collaboration and option agreement with Secarna Pharmaceuticals GmbH & Co. KG for RNA-based programs targeting rare renal indications. Protalix BioTherapeutics reported its third-quarter 2025 financial and business results. The stock price experienced a decline of 31.49% between May 8, 2025, and May 7, 2026.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)
Protalix Biotherapeutics, Inc. (PLX) Live Stock Price, Chart & Financial News | Edge Hound